The United Bio-Technology (Hengqin) Co., Ltd. focuses on the development of high-end biologics targeting major chronic diseases. Since its establishment in 2021, the company has continuously increased R&D investment, accelerated the transformation of research outcomes, and enhanced its core competitiveness. Currently, over 20 biologics projects are under research, including: UBT251 Injection, Semaglutide Injection, Romosozumab, Dupilumab, Insulin Degludec and Liraglutide Injection, and dual-target hypolipidemic drug.

Zhuhai United Bio-Pharmaceutical Co., Ltd. is committed to R&D in areas related to energy metabolism, inflammation, and autoimmune diseases, with a focus on developing high-end biologics for the treatment of major chronic illnesses. The company also engages in biopharmaceuticals, animal healthcare products, pharmaceutical excipients process optimization, manufacturing, sales, and technical services. The company has established well-developed platforms for strain preservation, fermentation process optimization, pharmaceutical intermediate products process R&D, purification process optimization, quality research, finished product research, and peptide drug technology development platform, and has built a first-class domestic R&D pipeline for diabetes biopharmaceuticals.

Established in 1998, the R&D Center of Zhuhai United Laboratories (Zhongshan) Co., Ltd. continues to expand its pharmaceutical research capabilities through independent innovation and external collaboration, developing more competitive products for the market. The Center comprises the following divisions: Chemical Drug Research Institute, Innovative Drug Research Institute, R&D Information Department, Regulatory Affairs Department, International Regulatory Affairs Department, and Project Management Department. It undertakes process development, quality research, industrialization research, and registration filing for both innovative chemical drugs and generic drugs. At present, there are more than 30 ongoing projects, covering four major categories including Class 1 chemical new drugs, chemical generic drugs, consistency evaluation of generic drugs, and health food. The Center has been recognized as a Guangdong Provincial Enterprise Technology Center, and has established a National Postdoctoral Research Station, the Guangdong Engineering R&D Center for Anti-infectives, the Guangdong Industry-College-Institute Demonstration Base for Anti-infectives, and a Technology Commissioner Workstation for Enterprises in Guangdong.

Established in 1998, the Chemical Drug Research Institute of Zhuhai United Laboratories Co., Ltd. set up a postdoctoral workstation in 2003 and formed a provincial-level Engineering Research and Development Center for Anti-infectives in 2005. The institute has been dedicated to process development and industrialization research of chemical drugs, establishing a distinctive R&D and scale-up system for chemical bulk medicines. It has strong capabilities in process development, industrial transformation, quality research, and registration filing, with chemical finished products R&D progressing rapidly. Current R&D pipeline include antibiotics, ophthalmology, immunology, metabolism, endocrinology, and dermatology, with over 20 ongoing projects.

Founded in 2013, the R&D Center of The United Laboratories (Inner Mongolia) Co., Ltd. focuses on the R&D of new products, new technologies, and new processes. Specializing in innovative R&D and process scale-up validation on biological fermentation, chemical and enzymatic synthesis, it has been accredited as 「Ezymatic Pharmaceutical Engineering Research Center」, 「Enterprise R&D Center」, 「Bio-Chemical Synthetic Drug R&D Center」 and 「Corporate Technology Center」 by Inner Mongolia Autonomous Region. Currently, the R&D Center maintains strategic industry-college-institute cooperation relationship with a great number of well-known scientific research colleges and R&D institutions, specializing in the development of pharmaceutical intermediate products, bulk medicines, cosmetic medicine chemicals, health foods and new bio-based new materials through biological fermentation as the core technology, supported by synthetic methods.

Established in 2015, the R&D Center of The United Animal Healthcare (Inner Mongolia) Co., Ltd. engages in the development of veterinary products primarily based on β-lactam compounds, covering livestock, poultry, aquaculture, and pet markets. The center is committed to building a well-known Chinese brand in veterinary β-lactam products. The R&D Center has achieved remarkable outcomes in independent innovation and process improvement, obtaining multiple invention patents, software copyrights, and new veterinary drug registration certificates. The center also led the formulation of the Standards for Testing of Amoxicillin and Clavulanic Acid Residues.

The Clinical Research Center of TUL Group (formerly the Medical Division) was established in 1996. It is responsible for the clinical research and development of all drugs and medical devices under the Group, including the formulation of overall clinical development strategies and pathways, study protocol design, trial organization and execution, project management and monitoring, quality control, and related tasks. Since its establishment, the Center has maintained close collaboration with nearly 300 national certified drug clinical trial institutions across China, particularly those with authority in relevant therapeutic areas, such as Peking Union Medical College Hospital, Chinese PLA General Hospital, Peking University People』s Hospital, and Beijing Tongren Hospital affiliated with Capital Medical University. Under the guidance of domestically and internationally renowned experts, the Center has completed nearly 120 drug clinical trials. At present, nearly 20 clinical studies are underway, with multiple innovative drugs, therapeutic biologics, and new generic chemical drugs scheduled to enter the clinical phase.